Patent ID: 8034827

Claim:
A new bradykinin B1 receptor antagonist phenanthridine compound of formula (I): wherein R 1 is hydrogen or C1-C4 alkyl; R 2 is selected from (1) hydrogen atom; with the proviso that R 1 and R 2 can not be simultaneously hydrogen atom; (2) —(CH 2 ) n —NR a R b , (3) —(CH 2 ) n CO—NR a R b , (4) —(CH 2 ) m —X-Q, and (5) —CHR c —NR a R b ; or R 1 and R 2 together with the nitrogen atom to which they are attached form a 4-7 membered heterocyclic ring containing 1-3 heteroatom(s) selected from O, S and N; wherein said ring is optionally substituted with —CO—NR a R b , C 1 -C 4 alkyl, 4-(4,5-dihydro-1H-imidazol-2-yl)-benzyl or 4-(1,4,5,6-tetrahydro-pyrimidin-2-yl)-benzyl; R 3 , R 4 , R 5 , R 6 and R 7 are independently selected from hydrogen, halogen, trifluoromethyl, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, and acetyl; n is an integer from 1 to 4; R a and R b are hydrogen atom, optionally substituted C 1 -C 4 alkyl group, or R a , R b and the nitrogen atom to which they are both attached together form a saturated, partially unsaturated or aromatic 4-7 membered ring containing 1-3 heteroatom(s) selected from 0, S and N; wherein said ring is optionally substituted with 1-piperidinyl, 2-piperidinyl, 4-piperidinyl, 2-pyridyl or 4-pyridyl group; R c is methyl, hydroxymethyl, benzyl or phenyl group; m is an integer from 0 to 6; X is a single bond, O or S; and, Q is a phenyl group, optionally substituted with [1,4′]bipiperidinyl-1′-yl, 4,5-dihydro-1H -imidazol-2-yl, —(CH 2 ) n NH—(C═NH)—NH 2 , or —(CH 2 ) m (C═NH)—NH 2 ; or a 4-piperidinyl group, optionally substituted with a 4-piperidinyl group; or a C 5 -C 7 cycloalkyl group, optionally substituted with a —(CH 2 ) m —NR a R b group; and optical antipodes, racemates, or salts thereof.